ITALIAN TRADE AGENCY

ITA Beijing Office

NEWSLETTER

HEALTHCARE
25 - 31 May 2025

Smart chronic disease management platform reduces heart failure hospitalizations by 33%
A nationwide smart chronic disease management platform for heart failure has reduced related hospitalizations by 33% in its first year. The platform uses wearable devices to monitor patients' vital signs and provides AI-powered early warnings to clinicians. Over 200,000 patients are enrolled, with 96% showing improved medication adherence. **(National Center for Cardiovascular Diseases)**

China launches first national ocular gene therapy dosing network
China has established its first national network for administering ocular gene therapies across 30 specialized hospitals. The network standardizes the complex procedure for treating inherited retinal diseases, reducing treatment delays from months to under two weeks. In the first quarter, 120 patients received sight-saving treatments through the coordinated system. **(National Clinical Research Center for Ocular Diseases).**

AI system predicts sepsis 10 hours earlier, reducing ICU mortality by 22%
An AI prediction system implemented in 200 ICUs nationwide can now detect sepsis 10 hours before clinical recognition, reducing mortality by 22%. The system analyzes 85 variables from electronic health records in real-time, achieving 94% prediction accuracy. False alerts have been reduced by 40% compared to previous versions. The technology is being integrated into all tertiary hospital ICUs by year's end. **(Chinese Journal of Critical Care Medicine)**

National elderly fall prevention program reduces hip fractures by 28%
A national program integrating home sensors and AI balance assessment has reduced fall-related hip fractures in the elderly by 28%. The system, deployed in 600,000 households, detects fall risks and provides personalized exercise plans via mobile app. High-risk individuals receive immediate caregiver alerts, cutting emergency response time from hours to minutes. The program is now part of basic public health services. **(National Institute of Geriatrics)**

3D bioprinted corneas restore vision in first-in-human trial
Chinese researchers have successfully restored vision in 10 patients using 3D bioprinted corneal implants in a first-in-human trial. The implants, created from the patient's own cells, achieved 20/40 vision or better in 80% of recipients in six months. The breakthrough provides a solution for the 10 million people awaiting corneal transplants globally. Regulatory approval for wider clinical use is anticipated within two years. **(Nature Biotechnology)**